Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 23, 2012Wed, February 22, 2012Tue, February 21, 2012Mon, February 20, 2012Sat, February 18, 2012Fri, February 17, 2012Thu, February 16, 2012Wed, February 15, 2012Tue, February 14, 2012Mon, February 13, 2012A Forward Look, the Year Ahead - Featured Research on Alnylam Pharmaceuticals, Inc. and ISIS Pharmaceuticals, Inc.
Published in Health and Fitness on Friday, February 17th 2012 at 6:06 GMT by Market Wire
February 17, 2012 09:00 ET
A Forward Look, the Year Ahead - Featured Research on Alnylam Pharmaceuticals, Inc. and ISIS Pharmaceuticals, Inc.
HONG KONG--(Marketwire - Feb 17, 2012) - Today, [ www.BollingerReport.com ] introduced featured coverage of Alnylam Pharmaceuticals, Inc. (
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Bollinger Report screened and selected Alnylam Pharmaceuticals, Inc. for its current position within the healthcare industry. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). The RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. A copy of this report featuring Alnylam Pharmaceuticals, Inc. (
Bollinger Report is featuring ISIS Pharmaceuticals, Inc. for its changing role within the healthcare industry. Isis Pharmaceuticals, Inc. (Isis) is engaged in antisense technology, exploiting a drug discovery platform to create a pipeline of drugs. The Company operates in two business segments: Drug Discovery and Development and Regulus Therapeutics Inc. To download researches and analysis on ISIS Pharmaceuticals, Inc. (
About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.
